Thymmune
Cambridge, US · 2 known investors
Thymmune Therapeutics develops a machine learning-driven thymic cell engineering platform that mass-produces iPSC-derived thymic cells to restore immune function affected by aging and disease. The company is building a pipeline of off-the-shelf cell therapies for immunodeficiencies, transplant-related, and autoimmune disorders.
Founders & leadership
SW
Stan WangMD, PhD
BL
Bing LimMD, PhD
MJ
Manish Jain